Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5348805 | 0.90 | CNR2 (0.47) | BCHEBRD4IDO1CNR2PIM1 | |
| SCHEMBL5106169 | 0.90 | TLR7 (0.40) | BCHEIDO1CNR2GBA1PIM1 | |
| SCHEMBL8135396 | 0.89 | PIM1 (0.47) | BCHEBRD4IDO1CNR2PIM1 | |
| SCHEMBL3093082 | 0.87 | GNRHR (0.39) | BCHEIDO1CNR2PIM1PIM3 | |
| SCHEMBL5113144 | 0.87 | TLR7 (0.48) | BCHEIDO1CNR2PIM1PIM3 | |
| SCHEMBL4333747 | 0.87 | TLR7 (0.46) | CNR2 | |
| SCHEMBL4343039 | 0.84 | BCHE (0.40) | BCHEIDO1CNR2GBA1 | |
| SCHEMBL5106852 | 0.83 | GBA1 (0.43) | BCHEBRD4CNR2GBA1 | |
| SCHEMBL1948125 | 0.80 | CNR2 (0.39) | BCHEIDO1CNR2PIM1PIM3 | |
| SCHEMBL5364581 | 0.80 | TLR7 (0.47) | BCHEIDO1CNR2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-7214675-B2 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-7115622-B2 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| US-7078523-B2 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050215581-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-29 | — | — | US | disclosed |
| US-20050148620-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-07-07 | — | — | US | disclosed |
| US-20050143413-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-06-30 | — | — | US | disclosed |
| US-20040097542-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | disclosed |
| US-20040072859-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | disclosed |
| US-20040067975-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-08 | — | — | US | disclosed |
| US-6677347-B2 | ANTICARCINOGENIC AND ANTITUMOR AGENTS; VIRICIDED, IMMUNOMODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-6664265-B2 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| US-6660735-B2 | Inducing cytokine biosynthesis; viral diseases, neoplastic disorders | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-09 | — | — | US | disclosed |
| US-20030187016-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | UBS AG, STAMFORD BRANCH | 2003-07-24 | — | — | US | disclosed |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187016-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | BCHE 4190/4885BRD4 25/4885IDO1 174/4885 |
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IRF3, IL2 | BCHE 4547/4885BRD4 51/4885IDO1 194/4885 |
| US-20050148620-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | BCHE 4547/4885BRD4 51/4885IDO1 194/4885 |
| US-20040072859-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | BCHE 2953/4885BRD4 82/4885IDO1 481/4885 |
| US-20050143413-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | BCHE 4190/4885BRD4 25/4885IDO1 174/4885 |
| US-20050215581-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | BCHE 2953/4885BRD4 82/4885IDO1 481/4885 |
| US-20040067975-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | BCHE 4190/4885BRD4 25/4885IDO1 174/4885 |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | BCHE 4547/4885BRD4 51/4885IDO1 194/4885 |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | BCHE 2953/4885BRD4 82/4885IDO1 481/4885 |
| US-20040097542-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | BCHE 4547/4885BRD4 51/4885IDO1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.